Pregabalin Capsule
Product Images NDC 72162-1544

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1544). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl721621544)

Label (Lbl721621544)
This is a medication description for Pregabalin capsules containing 100mg of the active ingredient. The medication should be kept out of reach of children and stored at room temperature between 20-25°C (68-77°F). The drug is packaged into 90 capsules by Bryant Ranch Prepack, Inc. and manufactured by ScieGen Pharmaceuticals Inc. The National Drug Code (NDC) for this medication is 72162-1544-9. It is only available with a prescription.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
The text provided is a table showing the percentage improvement in pain for patients who were administered Pregabalin 160 mg for three days. The table shows 100%, 2%, and 10% improvement for different time periods. The row headers are not clearly visible. The remaining part of the text is not relevant to the description.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
The text is a table showing the dosage of Fregabalin, Pregataiin, and Placebo for patients and the percent improvement in pain from baseline. The table also has a column labeled "Pacent of Patients Improved" with an unreadable set of numbers.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a table outlining the estimated percentage of subjects without LTR (unknown what LTR stands for) for a medication called "Progabain" and a placebo. The percentages range from 0% to 100% with intervals of 10%. The table also includes a timeline measured in days, with increments of 20 days up to 120 and then 160 and 180. It is unclear what the context or purpose of this table is.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
This appears to be a table presenting the percent improvement of subjects who took either pregabalin or a placebo from baseline to week 16. The subjects who took pregabalin seem to have a higher percent improvement compared to those who took placebo. The table also includes numerical values ranging from 100 to 280.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This appears to be a formula for calculating the creatinine clearance rate for a patient. The calculation involves subtracting the patient's age in years from 140, then multiplying that result by their weight in kilograms. For female patients, this number is then multiplied by 0.85. The final calculation involves multiplying 72 by the patient's serum creatinine level in milligrams per deciliter.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.